US Stock MarketDetailed Quotes

SGMO Sangamo Therapeutics

Watchlist
  • 1.100
  • +0.080+7.84%
Close Aug 12 16:00 ET
  • 1.100
  • 0.000-0.02%
Post 18:02 ET
229.04MMarket Cap-797P/E (TTM)

Sangamo Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
(Q3)Sep 30, 2022
Total revenue
-94.79%356K
-99.70%481K
58.34%176.23M
-92.50%2.04M
-64.48%9.4M
-76.73%6.84M
459.52%157.96M
0.54%111.3M
-2.70%27.23M
-7.36%26.46M
Operating revenue
-94.79%356K
-99.70%481K
58.34%176.23M
-92.50%2.04M
-64.48%9.4M
-76.73%6.84M
459.52%157.96M
0.54%111.3M
-2.70%27.23M
-7.36%26.46M
Cost of revenue
Gross profit
Operating expense
-54.13%36.27M
-41.42%47.66M
-5.55%295.22M
-22.77%63.81M
-12.72%71.01M
5.26%79.06M
10.70%81.35M
6.31%312.58M
21.71%82.62M
5.66%81.35M
Selling and administrative expenses
-24.78%12.05M
-35.12%11.77M
-2.42%61.17M
-20.34%13.1M
-14.29%13.92M
6.10%16.01M
21.65%18.14M
-0.85%62.68M
2.23%16.44M
11.98%16.24M
-General and administrative expense
-24.78%12.05M
-35.12%11.77M
-2.42%61.17M
-20.34%13.1M
-14.29%13.92M
6.10%16.01M
21.65%18.14M
-0.85%62.68M
2.23%16.44M
11.98%16.24M
Research and development costs
-61.58%24.22M
-43.22%35.89M
-6.34%234.06M
-23.38%50.71M
-12.33%57.09M
5.04%63.05M
7.91%63.22M
8.27%249.9M
27.76%66.18M
4.19%65.12M
Operating profit
50.28%-35.91M
-161.58%-47.18M
40.88%-118.99M
-11.50%-61.76M
-12.23%-61.61M
-57.92%-72.23M
269.25%76.61M
-9.79%-201.28M
-38.83%-55.39M
-13.33%-54.89M
Net non-operating interest income expense
-63.24%1.03M
-23.02%2.54M
17.71%11.1M
-59.43%1.49M
98.70%3.52M
6.02%2.8M
145.38%3.29M
76.43%9.43M
57.45%3.68M
112.11%1.77M
Non-operating interest income
----
----
17.71%11.1M
-59.43%1.49M
98.70%3.52M
----
----
76.43%9.43M
--3.68M
--1.77M
Total other finance cost
63.24%-1.03M
23.02%-2.54M
----
----
----
-6.02%-2.8M
-145.38%-3.29M
----
----
----
Other net income (expense)
97.72%-1.17M
92.57%-4.35M
-155.01M
-296K
-44.8M
-51.35M
-58.57M
Special income (charges)
97.72%-1.17M
92.57%-4.35M
---155.01M
---296K
---44.8M
---51.35M
---58.57M
--0
--0
--0
-Less:Impairment of capital assets
-97.72%1.17M
-92.57%4.35M
--155.01M
--296K
--44.8M
--51.35M
--58.57M
--0
--0
--0
Income before tax
70.15%-36.05M
-329.71%-48.99M
-37.04%-262.9M
-17.12%-60.57M
-93.68%-102.89M
-180.27%-120.77M
148.56%21.33M
-7.79%-191.85M
-37.67%-51.71M
-11.60%-53.13M
Income tax
101.18%74K
-49.48%98K
-1,282.28%-5.07M
-205.02%-272K
4,133.33%1.27M
-7,739.02%-6.26M
234.48%194K
40.20%429K
486.57%259K
-65.12%30K
Net income
68.45%-36.13M
-332.29%-49.09M
-34.09%-257.83M
-16.01%-60.3M
-95.96%-104.16M
-165.23%-114.51M
148.05%21.13M
-7.84%-192.28M
-38.61%-51.97M
-11.46%-53.16M
Net income continuous Operations
68.45%-36.13M
-332.29%-49.09M
-34.09%-257.83M
-16.01%-60.3M
-95.96%-104.16M
-165.23%-114.51M
148.05%21.13M
-7.84%-192.28M
-38.61%-51.97M
-11.46%-53.16M
Minority interest income
0
0
Net income attributable to the parent company
68.45%-36.13M
-332.29%-49.09M
-34.09%-257.83M
-16.01%-60.3M
-95.96%-104.16M
-165.23%-114.51M
148.05%21.13M
-7.85%-192.28M
-38.61%-51.97M
-11.46%-53.16M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
68.45%-36.13M
-332.29%-49.09M
-34.09%-257.83M
-16.01%-60.3M
-95.96%-104.16M
-165.23%-114.51M
148.05%21.13M
-7.85%-192.28M
-38.61%-51.97M
-11.46%-53.16M
Basic earnings per share
72.73%-0.18
-307.69%-0.27
-18.40%-1.48
-6.25%-0.34
-73.53%-0.59
-127.59%-0.66
143.33%0.13
-1.63%-1.25
-23.08%-0.32
-3.03%-0.34
Diluted earnings per share
72.73%-0.18
-325.00%-0.27
-18.40%-1.48
-6.25%-0.34
-73.53%-0.59
-127.59%-0.66
140.00%0.12
-1.63%-1.25
-23.08%-0.32
-3.03%-0.34
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022(Q3)Sep 30, 2022
Total revenue -94.79%356K-99.70%481K58.34%176.23M-92.50%2.04M-64.48%9.4M-76.73%6.84M459.52%157.96M0.54%111.3M-2.70%27.23M-7.36%26.46M
Operating revenue -94.79%356K-99.70%481K58.34%176.23M-92.50%2.04M-64.48%9.4M-76.73%6.84M459.52%157.96M0.54%111.3M-2.70%27.23M-7.36%26.46M
Cost of revenue
Gross profit
Operating expense -54.13%36.27M-41.42%47.66M-5.55%295.22M-22.77%63.81M-12.72%71.01M5.26%79.06M10.70%81.35M6.31%312.58M21.71%82.62M5.66%81.35M
Selling and administrative expenses -24.78%12.05M-35.12%11.77M-2.42%61.17M-20.34%13.1M-14.29%13.92M6.10%16.01M21.65%18.14M-0.85%62.68M2.23%16.44M11.98%16.24M
-General and administrative expense -24.78%12.05M-35.12%11.77M-2.42%61.17M-20.34%13.1M-14.29%13.92M6.10%16.01M21.65%18.14M-0.85%62.68M2.23%16.44M11.98%16.24M
Research and development costs -61.58%24.22M-43.22%35.89M-6.34%234.06M-23.38%50.71M-12.33%57.09M5.04%63.05M7.91%63.22M8.27%249.9M27.76%66.18M4.19%65.12M
Operating profit 50.28%-35.91M-161.58%-47.18M40.88%-118.99M-11.50%-61.76M-12.23%-61.61M-57.92%-72.23M269.25%76.61M-9.79%-201.28M-38.83%-55.39M-13.33%-54.89M
Net non-operating interest income expense -63.24%1.03M-23.02%2.54M17.71%11.1M-59.43%1.49M98.70%3.52M6.02%2.8M145.38%3.29M76.43%9.43M57.45%3.68M112.11%1.77M
Non-operating interest income --------17.71%11.1M-59.43%1.49M98.70%3.52M--------76.43%9.43M--3.68M--1.77M
Total other finance cost 63.24%-1.03M23.02%-2.54M-------------6.02%-2.8M-145.38%-3.29M------------
Other net income (expense) 97.72%-1.17M92.57%-4.35M-155.01M-296K-44.8M-51.35M-58.57M
Special income (charges) 97.72%-1.17M92.57%-4.35M---155.01M---296K---44.8M---51.35M---58.57M--0--0--0
-Less:Impairment of capital assets -97.72%1.17M-92.57%4.35M--155.01M--296K--44.8M--51.35M--58.57M--0--0--0
Income before tax 70.15%-36.05M-329.71%-48.99M-37.04%-262.9M-17.12%-60.57M-93.68%-102.89M-180.27%-120.77M148.56%21.33M-7.79%-191.85M-37.67%-51.71M-11.60%-53.13M
Income tax 101.18%74K-49.48%98K-1,282.28%-5.07M-205.02%-272K4,133.33%1.27M-7,739.02%-6.26M234.48%194K40.20%429K486.57%259K-65.12%30K
Net income 68.45%-36.13M-332.29%-49.09M-34.09%-257.83M-16.01%-60.3M-95.96%-104.16M-165.23%-114.51M148.05%21.13M-7.84%-192.28M-38.61%-51.97M-11.46%-53.16M
Net income continuous Operations 68.45%-36.13M-332.29%-49.09M-34.09%-257.83M-16.01%-60.3M-95.96%-104.16M-165.23%-114.51M148.05%21.13M-7.84%-192.28M-38.61%-51.97M-11.46%-53.16M
Minority interest income 00
Net income attributable to the parent company 68.45%-36.13M-332.29%-49.09M-34.09%-257.83M-16.01%-60.3M-95.96%-104.16M-165.23%-114.51M148.05%21.13M-7.85%-192.28M-38.61%-51.97M-11.46%-53.16M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 68.45%-36.13M-332.29%-49.09M-34.09%-257.83M-16.01%-60.3M-95.96%-104.16M-165.23%-114.51M148.05%21.13M-7.85%-192.28M-38.61%-51.97M-11.46%-53.16M
Basic earnings per share 72.73%-0.18-307.69%-0.27-18.40%-1.48-6.25%-0.34-73.53%-0.59-127.59%-0.66143.33%0.13-1.63%-1.25-23.08%-0.32-3.03%-0.34
Diluted earnings per share 72.73%-0.18-325.00%-0.27-18.40%-1.48-6.25%-0.34-73.53%-0.59-127.59%-0.66140.00%0.12-1.63%-1.25-23.08%-0.32-3.03%-0.34
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg
Concept Gene Editing
Gene Editing
Intraday-0.87%
Top Gainers Yesterday
Top Gainers Yesterday
Intraday-2.16%